Total Payments
$39,531
2024 Payments
$21,779
Companies
21
Transactions
261
Medicare Patients
14,768
Medicare Billing
$13.8M
Payment Breakdown by Category
Consulting$12,737 (32.2%)
Food & Beverage$9,784 (24.7%)
Travel$9,019 (22.8%)
Other$7,330 (18.5%)
Research$661.35 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,737 | 3 | 32.2% |
| Food and Beverage | $9,784 | 219 | 24.7% |
| Travel and Lodging | $9,019 | 26 | 22.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,316 | 6 | 18.5% |
| Unspecified | $661.35 | 6 | 1.7% |
| Honoraria | $13.73 | 1 | 0.0% |
Payments by Type
General
$38,870
255 transactions
Research
$661.35
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $11,775 | 51 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $9,401 | 68 | $0 (2024) |
| Janssen Research & Development, LLC | $4,855 | 19 | $0 (2022) |
| Genentech, Inc. | $3,231 | 4 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $2,764 | 13 | $0 (2024) |
| Astellas Pharma US Inc | $2,537 | 6 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,069 | 10 | $0 (2023) |
| Hoffmann-La Roche Limited | $1,012 | 4 | $0 (2017) |
| Allergan, Inc. | $868.51 | 26 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $677.61 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,779 | 64 | Genentech USA, Inc. ($9,893) |
| 2023 | $6,517 | 50 | Genentech, Inc. ($2,940) |
| 2022 | $6,103 | 50 | Janssen Research & Development, LLC ($4,855) |
| 2021 | $412.24 | 15 | Regeneron Healthcare Solutions, Inc. ($289.45) |
| 2020 | $513.11 | 16 | Regeneron Healthcare Solutions, Inc. ($233.52) |
| 2019 | $893.38 | 23 | Novartis Pharmaceuticals Corporation ($292.99) |
| 2018 | $760.24 | 18 | Allergan Inc. ($341.83) |
| 2017 | $2,553 | 25 | Hoffmann-La Roche Limited ($1,012) |
All Payment Transactions
261 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $29.39 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/26/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | Cash or cash equivalent | $141.26 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/26/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | Cash or cash equivalent | $11.91 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/21/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Ophthalmology | ||||||
| 11/19/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: Ophthalmology | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/17/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $401.18 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | In-kind items and services | $751.50 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $345.75 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/16/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | In-kind items and services | $218.68 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/15/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $25.38 | General |
| 11/14/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $31.03 | General |
| 11/14/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $4.26 | General |
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $99.18 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/28/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $29.71 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/24/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/22/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: Ophthalmology | ||||||
| 10/21/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $32.38 | General |
| Category: EYE CARE | ||||||
| 10/03/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $29.43 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/30/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/30/2024 | Genentech, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $141.03 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/27/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $661.35 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 4,010 | 20,437 | $15.7M | $3.8M |
| 2022 | 19 | 3,674 | 15,442 | $12.8M | $3.4M |
| 2021 | 19 | 3,513 | 13,389 | $7.9M | $3.0M |
| 2020 | 17 | 3,571 | 17,128 | $6.5M | $3.6M |
Total Patients
14,768
Total Services
66,396
Medicare Billing
$13.8M
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 269 | 3,070 | $7.7M | $2.1M | 27.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 81 | 1,747 | $1.7M | $328,577 | 18.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 942 | 2,831 | $1.0M | $257,840 | 24.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 467 | 2,308 | $1.4M | $218,073 | 15.6% |
| J3490 | Unclassified drugs | Office | 2023 | 33 | 86 | $498,900 | $164,183 | 32.9% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 62 | 638 | $622,400 | $137,447 | 22.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 17 | 4,140 | $517,500 | $120,249 | 23.2% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 28 | 721 | $309,309 | $114,408 | 37.0% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 28 | 825 | $302,503 | $99,298 | 32.8% |
| 92134 | Imaging of retina | Office | 2023 | 544 | 1,850 | $832,500 | $60,327 | 7.2% |
| J3590 | Unclassified biologics | Office | 2023 | 13 | 19 | $143,000 | $46,634 | 32.6% |
| 92250 | Photography of the retina | Office | 2023 | 907 | 1,155 | $224,070 | $32,932 | 14.7% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 101 | 285 | $202,048 | $20,458 | 10.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 136 | 136 | $63,920 | $16,738 | 26.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 92 | 204 | $52,836 | $14,412 | 27.3% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 48 | 65 | $10,725 | $3,319 | 30.9% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 153 | 247 | $28,405 | $3,118 | 11.0% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 44 | 65 | $8,320 | $2,567 | 30.9% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 22 | 22 | $9,482 | $2,229 | 23.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 23 | 23 | $8,579 | $2,184 | 25.5% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 240 | 2,764 | $6.3M | $2.0M | 31.4% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 106 | 3,131 | $2.8M | $697,203 | 24.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 875 | 2,660 | $823,410 | $246,615 | 30.0% |
| 67028 | Injection of drug into eye | Office | 2022 | 416 | 2,213 | $1.3M | $208,541 | 15.7% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2022 | 25 | 616 | $284,394 | $97,383 | 34.2% |
About Dr. Eric Suan, M.D
Dr. Eric Suan, M.D is a Ophthalmology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275536971.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Suan, M.D has received a total of $39,531 in payments from pharmaceutical and medical device companies, with $21,779 received in 2024. These payments were reported across 261 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($12,737).
As a Medicare-enrolled provider, Suan has provided services to 14,768 Medicare beneficiaries, totaling 66,396 services with total Medicare billing of $13.8M. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology
- Location Baltimore, MD
- Active Since 05/27/2005
- Last Updated 09/28/2012
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1275536971
Products in Payments
- Susvimo (Drug) $12,693
- EYLEA HD (Biological) $8,121
- EYP-1901 (Drug) $2,673
- Izervay (Drug) $2,469
- EYLEA (Biological) $1,262
- Lucentis (Biological) $1,124
- Non-Covered Product (Drug) $1,012
- OZURDEX (Drug) $996.95
- EYLEA AFLIBERCEPT INJECTION (Biological) $963.45
- Vabysmo (Drug) $696.84
- Syfovre (Drug) $369.58
- SUSVIMO (Drug) $304.51
- Cimerli (Biological) $155.46
- ILUVIEN (Drug) $86.06
- XIPERE (Drug) $78.13
- BEOVU (Drug) $74.14
- FINESSE SHARKSKIN (Device) $65.84
- Iluvien (Drug) $65.50
- VABYSMO (Drug) $42.46
- YUTIQ (Drug) $30.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Baltimore
Dr. Alfred Sommer, M.d, M.D
Ophthalmology — Payments: $3.7M
Ophthalmology $3.7M
Peter Mcdonnell
Ophthalmology — Payments: $2.2M
Ophthalmology $2.2M
Esen Akpek, M.d, M.D
Ophthalmology — Payments: $627,113
Ophthalmology $627,113
Neil Bressler, M.d, M.D
Ophthalmology — Payments: $524,415
Ophthalmology $524,415
Peter Campochiaro, M.d, M.D
Ophthalmology — Payments: $257,471
Ophthalmology $257,471
Jennifer Thorne, M.d, M.D
Ophthalmology — Payments: $201,745
Ophthalmology $201,745